-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Benzinga·07/28/2026 12:55:32
語音播報
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.